Waystar Patient Estimation

Waystar Patient EstimationWaystar Patient Estimation
Waystar Patient Estimation

Waystar Patient Estimation

Insurance Eligibility & Benefits Verification

DR 742017Active1716Louisville, United States
Rate

About

Waystar offers a comprehensive suite of revenue cycle management solutions for healthcare providers. Their platform includes tools for financial clearance, claim management, payment management, and denial prevention. Waystar serves a wide range of clients, including physician and specialty practices, ambulatory surgery centers, and health systems and hospitals.
Frequently asked

What does Waystar Patient Estimation do?

Waystar offers a comprehensive suite of revenue cycle management solutions for healthcare providers. Their platform includes tools for financial clearance, claim management, payment management, and denial prevention. Waystar serves a wide range of clients, including physician and specialty practices, ambulatory surgery centers, and health systems and hospitals.

What is Waystar Patient Estimation's valuation?

StartupHub estimates Waystar Patient Estimation's effective valuation at $2.7B (range $1.9B to $3.5B, 32% confidence), based on comparable companies in the sector.

How much funding has Waystar Patient Estimation raised?

Waystar Patient Estimation has raised a total of $3.7B in funding. The most recent round on record is IPO.

Where is Waystar Patient Estimation headquartered?

Waystar Patient Estimation is headquartered in Louisville, United States.

When was Waystar Patient Estimation founded?

Waystar Patient Estimation was founded in 2017.

What industry does Waystar Patient Estimation operate in?

Waystar Patient Estimation operates in Insurance Eligibility & Benefits Verification, HealthTech, Revenue Cycle Management, Patient Financial Experience, Healthcare Payments, InsurTech.

How many employees does Waystar Patient Estimation have?

Waystar Patient Estimation has approximately 1716 people on record.

HEADCOUNT
1716
DOMAIN RATING
74
Comments

No comments yet. Be the first to share your take.